title: Grey matter atrophy in patients suffering from multiple sclerosis.
abstract: White matter lesions are defining characteristics of multiple sclerosis (MS), whereas grey matter involvement is a less recognised attribute. Recent investigations using dedicated imaging approaches have made it possible to depict cortical lesions. Additionally, grey matter atrophy may be estimated using various methods. Several studies have suggested that grey matter atrophy closely correlates to clinical disability. In this review we have collected information on grey matter atrophy in MS and the effect of disease modifying therapies upon brain atrophy.
authors.forename: Zsigmond Tamás
authors.initials: ZT
authors.lastname: Kincses
authors.forename: Eszter
authors.initials: E
authors.lastname: Tóth
authors.forename: Nóra
authors.initials: N
authors.lastname: Bankó
authors.forename: Dániel
authors.initials: D
authors.lastname: Veréb
authors.forename: Nikoletta
authors.initials: N
authors.lastname: Szabó
authors.forename: Gergő
authors.initials: G
authors.lastname: Csete
authors.forename: Péter
authors.initials: P
authors.lastname: Faragó
authors.forename: András
authors.initials: A
authors.lastname: Király
authors.forename: Krisztina
authors.initials: K
authors.lastname: Bencsik
authors.forename: László
authors.initials: L
authors.lastname: Vécsei
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D001284:Atrophy / Q000175:diagnosis; D000068876:Fingolimod Hydrochloride; D000068717:Glatiramer Acetate; D066128:Gray Matter / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000008:administration & dosage; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology / Q000473:pathology* / Q000503:physiopathology; D018482:Muscle, Skeletal / Q000276:immunology; D000069442:Natalizumab; D010455:Peptides; D011237:Predictive Value of Tests; D011409:Propylene Glycols / Q000008:administration & dosage; D013110:Sphingosine / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000069442:Natalizumab; D010455:Peptides; D011409:Propylene Glycols; D000068576:Interferon beta-1b; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine; D000068556:Interferon beta-1a